Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have
no recent searches
You currently have no recent searches
Strosberg, Jonathan MD; Choi, Junsung MD; Nasir, Aejaz MD; Kvols, Larry MD
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas. In-vitro data indicates that the combination of capecitabine and temozolomide is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. We evaluated the efficacy of capecitabine and temozolomide in 33 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS) and overall survival (OS).
Patients with metastatic, differentiated pancreatic endocrine carcinomas who had not received prior systemic chemotherapy were treated with capecitabine 750 mg/m2 twice daily days 1-14 and temozolomide 200 mg/m2 once daily days 10-14 every 28 days. Response rates were assessed by RECIST criteria.
Among 33 patients treated, 22 (67%) patients achieved an objective radiographic response. Median progression-free survival was 18 months. The rate of survival at two years was 92%. Only four patients (12%) experienced grade 3 or 4 adverse events.
The combination of capecitabine and temozolomide is associated with an exceptionally high and durable response rate in metastatic endocrine carcinomas of the pancreas. Clinical endpoints, including response rate, survival and toxicity, are superior to those observed with streptozocin-based regimens.
© 2010 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Pancreas.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in for
days or until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection